NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024

Rhea-AI Summary

NRx Pharmaceuticals, Inc. (NRXP) will release its Q4 and full year 2023 financial results on March 28, 2024. A conference call to discuss the results and provide a corporate update will be held at 4:30 p.m. ET on the same day.

RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30 p.m. ET the same day.

A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-877-704-4453, Int'l Investors Dial 1-201-389-0920.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-a-corporate-update-on-march-28-2024-302096432.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When will NRx Pharmaceuticals release its Q4 and full year 2023 financial results?

NRx Pharmaceuticals will release its Q4 and full year 2023 financial results after the market closes on Thursday, March 28, 2024.

How can I access the press release with the financial results?

The press release with the financial results will be available on NRx Pharmaceuticals' website at https://ir.nrxpharma.com/press-releases.

How can I join the conference call to discuss the financial results and corporate update?

You can join the conference call via a live webcast on NRx Pharmaceuticals' website at https://ir.nrxpharma.com/events or by dialing 1-877-704-4453 domestically or 1-201-389-0920 for international investors.